FDA Submits Interim Peptide Compounding Policy for White House Review: What Pharmacies Should Know
Overview of the Regulatory Action According to a client alert from the law firm Buchanan Ingersoll & Rooney PC, the U.S.
Pharmacists Must Guide Peptide Talks Pending FDA Action | NCPA 2026
Pharmacists Must Guide Peptide Talks Pending FDA Action, NCPA 2026 Session Signals Pharmacists are being urged to take a proactive role in counseling patients on peptide therapies even as the Food and Drug Administration continues to weigh how it will regulate this fast-growing category of compound...
Houston Pharmacy Behind Recalled Compounded Tirzepatide Vials Drew 14 FDA Inspection Observations, Including Exposed Skin and Research-Grade Ingredients
Houston Compounding Pharmacy Faces Scrutiny After FDA Finds 14 Violations Tied to Recalled Tirzepatide Vials A Houston-based compounding pharmacy linked to a recall of compounded tirzepatide injectable vials was cited by the U.S.
US FDA takes step to change peptide compounding policy
Overview of the Regulatory Action Reuters has reported that the U.S. Food and Drug Administration is moving to revise its policy governing the compounding of peptide drugs, a category of therapeutics that has exploded in popularity and regulatory scrutiny over the past several years.
FDA Peptide Compounding Policy: What a Temporary Enforcement Reprieve Could Mean for Pharmacies
Overview of the Regulatory Action The compounding pharmacy industry received notable, if temporary, relief in a recent regulatory development concerning peptide products, as reported by law firm Buchanan Ingersoll & Rooney PC. According to the firm's analysis, the U.S.
fda approved peptide drugs for weight loss 2026
FDA's Peptide Weight-Loss Pipeline Faces Scrutiny as 2026 Approvals Loom Regulatory attention on peptide-based weight-loss drugs is intensifying as the pharmaceutical industry anticipates a new wave of potential FDA approvals in 2026.
FDA Recalls and Warnings: Sterility Issues With Compounded GLP-1s, Foreign Pills in Generic Reglan Bottles
FDA Recalls and Warnings: Sterility Issues With Compounded GLP-1s, Foreign Pills in Generic Reglan Bottles The U.S.
Pharmacy Law Lowdown: FDA’s Evaluation of Peptides
Pharmacy Law Lowdown: FDA's Evaluation of Peptides The U.S. Food and Drug Administration's ongoing scrutiny of peptide products is once again in the spotlight, following a report published by Drug Topics under its "Pharmacy Law Lowdown" series examining the agency's evaluation of peptides.
The FDA Is Struggling To Police The Peptide Boom
The FDA Is Struggling To Police The Peptide Boom The Food and Drug Administration is facing mounting difficulty controlling the rapid proliferation of therapeutic and performance-enhancing peptides flooding the American marketplace, according to a Forbes report examining the agency's regulatory gap...
FDA warns about some peptide injections possibly linked to illnesses
FDA Warns About Some Peptide Injections Possibly Linked to Illnesses The U.S. Food and Drug Administration has issued a warning regarding certain peptide injections that may be associated with reported illnesses, according to a report from NBC News.
FDA Warning Letter to Empower Pharmacy and What It Means for 503A Compounding Pharmacies
FDA Warning Letter to Empower Pharmacy Signals Heightened Scrutiny of 503A Compounders The U.S. Food and Drug Administration has issued a warning letter to Empower Pharmacy, one of the nation's largest compounding pharmacies, according to reporting from the law firm Buchanan Ingersoll & Rooney PC.
FDA Recalls and Warnings: Glutathione Peptide Injections Recalled Over Endotoxin Contamination
FDA Recalls and Warnings: Glutathione Peptide Injections Recalled Over Endotoxin Contamination Federal regulators have flagged injectable glutathione products for endotoxin contamination, according to a report from MedShadow.
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
Overview of the Regulatory Action A recent Food and Drug Administration advisory panel vote has reignited debate over how the agency should regulate the rapidly growing category of therapeutic peptides, according to a report from AJMC (American Journal of Managed Care).
China's Shengnuo Subsidiary Hit with FDA Import Ban, All Peptide API Sales to US Suspended
China's Shengnuo Subsidiary Hit with FDA Import Ban, All Peptide API Sales to US Suspended The U.S.
Federal regulators and state boards crack down on RUO peptides
Federal and State Regulators Intensify Scrutiny of "Research Use Only" Peptides Federal agencies and state licensing boards are ramping up enforcement against the sale and clinical use of "research use only" (RUO) peptides, a category of compounds that has proliferated in wellness clinics, teleheal...
Will an FDA crackdown curb access to cheaper GLP-1 weight-loss drugs? Here's what to know.
FDA Crackdown on Compounded GLP-1 Drugs Raises Access and Affordability Concerns The Food and Drug Administration's ongoing enforcement actions against compounded versions of popular GLP-1 weight-loss medications are raising new questions about whether millions of Americans will lose access to lowe...
‘Peptide Party’ in Bengaluru cancelled after FDA raises regulatory, safety concerns
‘Peptide Party’ Event in Bengaluru Called Off Amid FDA Scrutiny A gathering billed as a “Peptide Party” scheduled to take place in Bengaluru has been cancelled after regulatory and safety concerns were raised, according to a report from The New Indian Express.
The Best FDA Decision On Peptide Authorization Isn’t Yes Or No
The Best FDA Decision On Peptide Authorization Isn't Yes Or No The Food and Drug Administration's approach to regulating therapeutic peptides has reached an inflection point, and according to a recent analysis published by Forbes, the most consequential path forward for the agency may not be a simp...
Phoenix doctor urges caution as FDA moves to regulate popular peptides
Phoenix Doctor Urges Caution as FDA Moves to Regulate Popular Peptides A Phoenix-based physician is warning consumers to exercise caution amid growing regulatory scrutiny of peptide therapies, as the U.S.
FDA issues warning letters to five unapproved GLP-1 websites
FDA Issues Warning Letters to Five Unapproved GLP-1 Websites The U.S. Food and Drug Administration has issued warning letters to five websites for allegedly marketing unapproved versions of GLP-1 receptor agonist products, according to a report from pharmaphorum.com.
FDA cracks down on online black market for weight loss peptides
FDA Targets Illicit Online Sales of Weight Loss Peptides Amid Surging Demand The U.S. Food and Drug Administration is intensifying scrutiny of an expanding online black market for weight loss peptides, according to a report from Pharmaceutical Technology.
Aurobindo Pharma’s Auropeptides US FDA Inspection Ends With One Finding
Aurobindo Pharma's Peptide Manufacturing Unit Clears FDA Inspection With Single Observation Aurobindo Pharma's specialized peptide manufacturing subsidiary, Auropeptides, has concluded a US Food and Drug Administration inspection with only one observation noted, according to a report by Sahi.
Hims Stock Slips Overnight As FDA Warns Telehealth Firms Over GLP-1 Claims — Why Traders Think The ‘Overhang’ Won’t Last
Hims & Hers Shares Dip as FDA Signals Scrutiny of GLP-1 Marketing by Telehealth Providers Shares of Hims & Hers Health slipped in overnight trading after reports emerged that the U.S.
The FDA Is Right to Prohibit Mass Production of Unapproved GLP-1 Drugs
FDA Is Right to Prohibit Mass Production of Unapproved GLP-1 Drugs, Legal Experts Say The Food and Drug Law Institute (FDLI) has weighed in on one of the most contentious regulatory disputes in pharmaceutical law today, arguing that the Food and Drug Administration's efforts to curb mass production...
5 Things to Know About the FDA's Peptide Reversal
FDA's Shifting Stance on Peptides Sends Ripples Through Compounding Industry The U.S.
FDA Advisory Committee Voted Yes on Six Peptides. Now What? The Regulatory Road Ahead
FDA Advisory Committee Voted Yes on Six Peptides.
July 27, 2026: FDA peptide panel narrowly votes to add unapproved drugs to compounding list
FDA Advisory Panel Narrowly Approves Adding Unapproved Peptides to Compounding List A Food and Drug Administration advisory panel voted narrowly on July 27, 2026, to recommend adding certain unapproved peptide drugs to the agency's compounding lists, according to reporting from the Partnership for ...
FDA on Peptides: A New Landscape for Compounders
FDA on Peptides: A New Landscape for Compounders Washington, D.C.
An FDA Advisory Panel Voted to Ease Restrictions on 6 Controversial Peptides—Here’s What That Means
FDA Advisory Panel Reportedly Backs Loosening Restrictions on Six Contested Peptides A Food and Drug Administration advisory panel has reportedly voted in favor of easing restrictions on six peptides that have been at the center of an ongoing regulatory dispute, according to a report from Allure.
Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides
Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides State legislatures and pharmacy boards across the country are moving to impose their own restrictions on compounded GLP-1 medications and peptide products, adding a new layer of regulatory complexity for an industry t...
Are Peptides Illegal in California? State Laws Explained
Are Peptides Illegal in California? What the Current Rules Actually Say Confusion over the legal status of therapeutic peptides — from BPC-157 to CJC-1295 and semaglutide-adjacent compounds — has intensified as more Californians turn to wellness clinics, telehealth providers, and compounding ph...
Texas Peptide Laws 2024: Regulations for BPC-157, TB-500, and More
Texas Peptide Laws 2024: What Residents and Businesses Need to Know About BPC-157, TB-500, and Compounded Peptide Therapies As interest in peptide therapies such as BPC-157 and TB-500 continues to grow among Texas consumers, wellness clinics, and compounding pharmacies, questions about the state's ...
FDA panel supports broadening access to peptides popular on the gray market
FDA Advisory Panel Signals Openness to Expanding Legal Access to Popular Peptide Compounds A Food and Drug Administration advisory panel has expressed support for broadening legitimate access to certain peptide compounds that have gained significant popularity through gray-market channels, accordin...
How the FDA Regulates Peptides
How the FDA Regulates Peptides: A Growing Regulatory Gray Zone Under Scrutiny The Food and Drug Administration's oversight of peptide-based products has come under renewed examination, as a new analysis from the Johns Hopkins Bloomberg School of Public Health lays out the complex and often confusin...
FDA staff and peptide enthusiasts set to clash at advisory panel
FDA Advisory Panel Set to Weigh In on Contested Peptide Compounds Amid Growing Industry Tension A forthcoming Food and Drug Administration advisory committee meeting is expected to become a flashpoint in the ongoing debate over the regulatory status of popular research and wellness peptides, accord...
FDA’s Review Of Peptides Signals A Growing Public Health Challenge—Separating Science From Hype
FDA's Review Of Peptides Signals A Growing Public Health Challenge—Separating Science From Hype A recent Forbes report has drawn renewed attention to the Food and Drug Administration's ongoing scrutiny of the peptide industry, highlighting what the publication frames as a growing public health ch...
FDA panel backs 6 peptides despite its own scientists’ objections
FDA Panel Backs Six Peptides Despite Internal Scientific Objections A Food and Drug Administration advisory panel has voted to support the use of six peptide compounds for compounding, moving forward despite documented objections from the agency's own scientific staff, according to a report from Ma...
FDA puts former Rancho Santa Fe pharmacist on notice for selling unapproved weight-loss injections online
FDA Targets Former Rancho Santa Fe Pharmacist Over Online Weight-Loss Injection Sales The U.S.
July 27, 2026: FDA peptide panel narrowly votes to add unapproved drugs to compounding list
FDA Advisory Panel Narrowly Approves Adding Unapproved Peptides to Compounding List A Food and Drug Administration advisory panel voted narrowly on July 27, 2026, to recommend adding a group of unapproved peptide drugs to the agency's compounding list, according to reporting from the Partnership fo...
FDA advisers back first four of seven unapproved peptides under review for looser rules
FDA Advisory Panel Recommends Looser Rules for Four Unapproved Peptides, With Three More Under Review A Food and Drug Administration advisory committee has voted to support looser regulatory treatment for four of seven unapproved peptide compounds currently under agency review, according to a repor...
FDA panel to review popular peptides amid persistent consumer appetite
FDA Panel to Review Popular Peptides Amid Persistent Consumer Appetite The U.S.
FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists
FDA Advisory Panel Backs Expanded Peptide Compounding Over Objections From Agency's Own Scientists A Food and Drug Administration advisory panel has voted to recommend adding certain peptides to the list of substances that compounding pharmacies are permitted to use, a decision reached despite push...
FDA panel votes to loosen restrictions for controversial peptides
FDA Advisory Panel Votes to Ease Restrictions on Controversial Peptide Compounds A Food and Drug Administration advisory panel has voted to loosen restrictions on a category of peptide compounds that have been at the center of an ongoing regulatory debate, according to a report from the BBC.
An FDA Committee Just Voted in Favor of Peptides—Despite the Agency's Opposition
FDA Advisory Panel Breaks With Agency Staff, Backs Continued Access to Peptide Compounds A Food and Drug Administration advisory committee has voted in favor of preserving broader access to certain peptide-based compounds, setting up a notable clash with the agency's own staff recommendations, acco...
FDA Panel to Revisit Biden Peptide Ban as It Weighs Looser Rules
FDA Panel to Revisit Biden-Era Peptide Restrictions Amid Push for Regulatory Flexibility A Food and Drug Administration advisory panel is preparing to reexamine restrictions placed on a category of therapeutic peptides during the Biden administration, according to a report from Bloomberg Law News.
Compounded GLP-1s: Why doctors worry and the FDA is cracking down
Compounded GLP-1s: Why Doctors Worry and the FDA Is Cracking Down The explosive popularity of GLP-1 receptor agonists like semaglutide and tirzepatide for weight loss and diabetes management has spawned a booming secondary market: compounded versions of these drugs, sold at a fraction of brand-name...
Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides
Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides As federal oversight of compounded GLP-1 medications and research peptides continues to evolve at the U.S.
Why Did Peptide Sciences Shut Down? Timeline, FDA Pressure, and What It Means for the Industry
Peptide Sciences, the largest gray-market research peptide vendor in the U.S., voluntarily shut down on March 6, 2026. A breakdown of the FDA enforcement actions, pharmaceutical lawsuits, and new legislation that led to the closure.
FDA Peptide Category 1 vs Category 2: Complete List and What It Means for Access
Understanding the FDA's Category 1 and Category 2 bulk drug substance classifications for peptides, which compounds fall into each group, and how 2026 reclassification proposals could reshape compounding pharmacy access.
Are Peptides Legal for Veterinary Use? FDA, DEA, and State Regulations
A detailed look at the legal framework governing peptide use in animals, including FDA animal drug rules, extra-label use under AMDUCA, DEA scheduling considerations, and state veterinary board regulations.